Premium
Are all patients with psoriasis at increased risk for coronary artery disease?
Author(s) -
Seremet Sila,
Genc Berhan,
Tastan Ahmet,
Akyildiz Zehra Ilke,
Nazli Cem,
Ozcelik Sinan,
Afsar Fatma Sule,
Solak Aynur,
Emren Volkan
Publication year - 2015
Publication title -
international journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 93
eISSN - 1365-4632
pISSN - 0011-9059
DOI - 10.1111/ijd.12673
Subject(s) - medicine , psoriasis , agatston score , cardiology , coronary atherosclerosis , coronary artery disease , calcification , framingham risk score , disease , coronary artery calcium , dermatology
Associations have been recently recognized between psoriasis and an increased incidence of atherosclerotic diseases. However, there are scarce data on the prevalence of coronary lesions in patients with psoriasis. The aim of this study was to identify the calcified and non‐calcified atherosclerotic coronary lesions in patients with psoriasis compared to controls. Forty patients with psoriasis and 42 control subjects matched for age, sex, and cardiovascular risk profile were included in this case–control study. Coronary lesions were evaluated by a 128‐slice dual source multidetector computed tomography scanner. Coronary calcification scoring was calculated according to the Agatston score. The prevalence of atherosclerotic coronary lesions (psoriasis: 15%, controls: 16.7%; P = 0.83) and the mean coronary calcification scoring (psoriasis: 9.9 ± 35.2 Agatston unit, controls 2.8 ± 12.0 Agatston unit; P = 0.81) did not show a significant difference between the two groups. Multivariate analysis identified age ≥48 years and fasting blood glucose ≥99.0 mg/dl as independent predictors of coronary artery disease in patients with psoriasis ( F = 30.9; P = 0.001; adjusted R 2 = 0.49). Patients with psoriasis had the same prevalence of calcified and non‐calcified atherosclerotic coronary lesions as compared to controls. Our results demonstrated the necessity of considering the age and fasting blood glucose of patients with psoriasis in a decision for further cardiovascular evaluation.